^
Association details:
Biomarker:FGFR1 rearrangement + Chr t(8;13)
Cancer:Lymphoma
Drug Class:Tyrosine kinase inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Source:
Title:

Myeloid/lymphoid neoplasm with FGFR1 rearrangement

Published date:
09/09/2021
Excerpt:
A 25-year-old man presented...cytometry analysis confirmed involvement by T-lymphoblastic leukemia/lymphoma...An FGFR1 (8p11) gene rearrangement was detected in the lymph node...Cytogenetics revealed t(8;13) in the bone marrow (panel D)...myeloid neoplasms exhibit chemoresistance to first- and second-generation tyrosine kinase inhibitors (TKIs).
DOI:
https://doi.org/10.1182/blood.2021012168